1. Introduction {#sec1}
===============

Glucagon is a 29 amino acid peptide hormone secreted from pancreatic islet α-cells that plays a critical role in maintenance of euglycemia, predominantly by increasing hepatic glucose output. Activation of glucagon receptor (Gcgr) signaling promotes glycogenolysis and enhanced gluconeogenesis, and regulates pathways controlling hepatic lipid oxidation and lipid secretion. Although the actions of glucagon are classically viewed as essential for prevention of hypoglycemia in the face of limited nutrient availability or excess insulin action [@bib1], Gcgr signaling also controls cell survival pathways, as genetic interruption of Gcgr signaling increases the susceptibility to hepatic injury [@bib2].

A single Gcgr is expressed not only in liver, but in extrahepatic tissues including the central and peripheral nervous system, pancreatic islets, adipose tissue, kidney, blood vessels and heart [@bib3; @bib4]. In the pancreas, glucagon potentiates glucose-dependent insulin secretion, whereas activation of Gcgr signaling in the brain regulates hepatic glucose production, control of appetite and body weight [@bib5]. Glucagon actions in adipose tissue and kidney are less understood, but have been linked to control of fatty acid and glucose metabolism.

Although glucagon levels normally decrease during a meal, glucagon secretion is inappropriately increased in many subjects with type 2 diabetes (T2D) [@bib1; @bib6]. Over the last several decades, experimental studies attenuating glucagon action using glucagon immunoneutralizing antisera, Gcgr antagonists, antisense *Gcgr* oligonucleotides and *Gcgr*^−/−^ mice have demonstrated amelioration of hyperglycemia in experimental models of diabetes [@bib1; @bib7]. Collectively, these findings have raised enthusiasm for glucagon antagonism as a potential therapeutic strategy for T2D. Indeed, GCGR antagonists and antisense oligonucleotides targeting hepatic GCGR expression robustly lower glucose in clinical trials of human subjects with T2D. However, mechanism-based toxicities noted in preclinical studies, including dyslipidemia, and transaminase elevations [@bib2; @bib8], have also been reported in clinical studies. Hence, the risk:benefit proposition for partial attenuation of GCGR signaling in diabetic humans requires further evaluation.

Complementary efforts are exploring whether partial enhancement of glucagon action, together with agonism of the glucagon-like peptide-1 receptor (GLP-1R), may be useful for the treatment of diabetes and/or obesity [@bib9; @bib10]. Oxyntomodulin, a naturally occurring proglucagon-derived peptide, contains the 29 amino acid sequence of glucagon plus a carboxyterminal extension and exerts potent glucoregulatory and anorectic actions in rodents and humans through activation of the GLP-1 and glucagon receptors [@bib11; @bib12]. More recent studies have demonstrated that simultaneous activation of the glucagon and GLP-1 receptors using synthetic balanced co-agonists produces potent glucoregulatory activity and greater weight loss than observed with GLP-1R agonists alone [@bib13]. Hence there is also considerable interest in understanding the metabolic consequences and therapeutic potential arising from partial selective activation of GCGR signaling.

The increasing interest in development of drugs that reduce or activate GCGR signaling for the treatment of metabolic disorders such as diabetes and obesity raises important questions about the cardiovascular actions and safety of such agents. Current understanding of glucagon action in the heart is limited, and activation of Gcgr signaling in this organ has been reported to be either beneficial or harmful, depending on the experimental or clinical context [@bib14; @bib15; @bib16; @bib17]. We have now examined the consequences of manipulating Gcgr signaling in the non-diabetic ischemic mouse heart. Our findings reveal that exogenous glucagon impairs survival following ligation of the left anterior descending (LAD) coronary artery, actions requiring p38 MAP kinase. In contrast, *Gcgr*^CM−/−^ mice with cardiac-specific inactivation of the *Gcgr* display a cardioprotective phenotype, associated with reduced accumulation of incompletely oxidized fatty acid metabolites in the heart. These findings have implications for pharmaceutical efforts directed at manipulating GCGR signaling for the treatment of human disease.

2. Methods {#sec2}
==========

2.1. Mice and reagents {#sec2.1}
----------------------

Inducible αMHC^Cre^ (stock 005657) [@bib18] and FLPe (stock 005703) transgenic mice in the C57BL/6 background were obtained from the Jackson Laboratory. *Gcgr*^CM−/−^ mice were generated by crossing *αMHC*^Cre^ mice with *Gcgr*^Flox^ mice [@bib19] in the C57BL/6 background. LAD coronary artery ligation was used to induce myocardial infarction (MI) in 12--14-week-old male mice as described in Ref. [@bib20]. All mice were housed (5 per cage) under a light/dark cycle of 12 h in the Toronto Centre for Phenogenomics (TCP) animal facility, with free access to food and water except where noted. All procedures were conducted according to protocols and guidelines approved by the TCP Animal Care Committee. Genotypes were determined through analysis of genomic DNA prepared from tail snips. Tamoxifen (Sigma Aldrich, 50 mg/kg) dissolved in corn oil was administered for 5 consecutive days to 6- or 7-week-old male *αMHC*^Cre^ or *Gcgr*^CM−/−^ mice to induce Cre expression. Before any cardiac assessment or procedure, all mice were allowed 6 weeks to recover after the last tamoxifen injection, as Cre expression in the heart often induces a transient cardiomyopathy that dissipates 5 weeks after tamoxifen-induced Cre expression [@bib21]. Glucagon (Sigma) 30 ng/g body weight or saline in 10% gelatin was administered to C57BL/6 mice as described in Ref. [@bib8], 3 injections daily, with or without 2 injections daily of 1 μmol/g body weight SB203580 (p38 MAPK inhibitor, Sigma) for 7 days. Blood pressure and heart rates were measured using a telemetry system (DSI technology) as described in Ref. [@bib22]. The rat *Gcgr* adenovirus (Ad*Gcgr*) has been described previously in Ref. [@bib2].

2.2. Ischemia/reperfusion {#sec2.2}
-------------------------

Global no-flow ischemia in Langendorff-perfused hearts was induced as described in Ref. [@bib23]. Hearts underwent a 30 min aerobic perfusion with Krebs-Henseleit buffer, followed by a 30 min global no-flow ischemia, and either a 50 or 60 min reperfusion period during which left ventricular developed pressure (LVDP) was recorded (Biopac Systems Canada Inc.). In a separate set of hearts 1 μg/mL glucagon was administered 20 min prior to ischemia.

2.3. Myocardium metabolic profiling {#sec2.3}
-----------------------------------

Mass spectrometry-based metabolic profiling was performed to determine myocardial levels of acylcarnitines and organic acids [@bib24]. Triacylglycerol (TAG) was extracted from frozen myocardial tissue (∼20 mg) with a 2:1 chloroform-methanol solution and quantified with a commercially available enzymatic assay kit (Wako Pure Chemical Industry) as described in Ref. [@bib25].

2.4. Heart histology {#sec2.4}
--------------------

Animals were anesthetized using avertin (250 mg/kg body weight ip injection). The chest cavity was opened to expose the heart and 1 M KCl was injected into the apex to arrest the heart in diastole. The heart was perfusion-fixed with 4% buffered formalin at physiological pressure, post-fixed in formalin, embedded in paraffin, and sectioned at 6 μm, and stained with Masson\'s Trichrome or processed for Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). TUNEL staining was performed using the ApopTag peroxidase kit for apoptosis (EMD Millipore). Cardiac morphometry was performed on mid-ventricular cross-sections using Aperio ImageScope Viewer software (Aperio Technologies). The infarcted area was calculated as a % of total LV area. Cardiac hypertrophy was quantified as the heart weight-to-body weight ratio.

2.5. Glucose tolerance {#sec2.5}
----------------------

12--14-week-old male mice were fasted overnight (16--18 h), and glucose (1.5 mg/g body weight) was administered orally (through a gavage tube) or via injection into the peritoneal cavity (intraperitoneal glucose tolerance test). Blood samples were drawn from the tail vein at 0, 15, 30, 60, 90, and 120 min post-glucose administration, and blood glucose and insulin levels were measured as described in Ref. [@bib26].

2.6. Western blotting {#sec2.6}
---------------------

Hearts were collected from fasted mice (5 h) 30 min following ischemia or sham surgery, washed in Krebs buffer containing 11 mM glucose and frozen. Frozen hearts were powdered and homogenized in buffer containing 50 mM Tris HCl, pH 8, 1 mM EDTA, 10% glycerol, 0.02% Brij-35. Western blotting was carried out as described in Refs. [@bib27; @bib28] and blots were visualized using an enhanced chemiluminescence Western blot detection kit (Perkin Elmer) and quantified with Carestream Molecular Imaging Software (Kodak).

2.7. RNA analyses {#sec2.7}
-----------------

RNA was isolated from cardiac extracts using TRI reagent (Sigma). First-strand cDNA was synthesized from total RNA using the SuperScript III reverse transcriptase synthesis system (Invitrogen). Real-time polymerase chain reaction was performed with the ABI Prism 7900 Sequence Detection System using TaqMan Gene Expression Assays and TaqMan Universal PCR Master Mix (Applied Biosystems). Relative levels of mRNA transcripts were quantified using the 2-ΔCt method and normalized to levels of peptidyl-prolyl isomerase A (*Ppia*-cyclophilin) RNA.

2.8. Cell culture {#sec2.8}
-----------------

Atrial cardiomyocytes were isolated as described in Ref. [@bib22]. HL-1 atrial cardiac myocytes were provided by Dr. William Claycomb (Louisiana State University, New Orleans), and cultured in Claycomb Media (Sigma--Aldrich) with 10% FBS, 1% penicillin/streptomycin, 0.1 mM norepinephrine, and 2 mM [l]{.smallcaps}-glutamine. Cells were seeded onto 6-well plates (BD Falcon) coated with 0.02% gelatin/0.5% fibronectin. Confluent cells were serum-starved and supplemented with Claycomb Media without FBS and norepinephrine prior to infection with Ad*β-Gal* or Ad*Gcgr* at 10× multiplicity of infection. 24 h following infection, cells were treated with either PBS or glucagon for 3 h in supplemented Claycomb Media without FBS and norepinephrine. Cellular injury was induced by H~2~O~2~ [@bib29].

2.9. Statistical analysis {#sec2.9}
-------------------------

Results are presented as mean ± SEM. Statistical significance was determined using 1- or 2-way analysis of variance with Bonferroni post hoc tests (as appropriate) using GraphPad Prism 4.0 (GraphPad Software Inc). Statistical significance was noted when *p* \< 0.05.

3. Results {#sec3}
==========

3.1. Glucagon impairs outcomes during experimental MI in a p38 MAPK-dependent manner {#sec3.1}
------------------------------------------------------------------------------------

As recent studies of the related *Glp1r* revealed issues with receptor localization and surprising chamber-specific receptor expression [@bib22; @bib30; @bib31], we first assessed *Gcgr* expression in the mouse heart using both regular PCR and primers corresponding to the full length open reading frame, as well as quantitative real-time PCR ([Supplementary Figure 1A,B](#appsec2){ref-type="sec"}). Consistent with a previous report in Ref. [@bib32], *Gcgr* expression was most abundant in RNA from the right atria but easily detectible in RNA from both right and left ventricle. In contrast, *Glp1r* expression was restricted to the atria as previously described in Refs. [@bib22; @bib32]. The expression of the *Gipr* was much less atrial-biased, relative to the *Glp1r*, whereas *Glp2r* mRNA transcripts were not detected in the mouse heart ([Supplementary Figure 1A,B](#appsec2){ref-type="sec"}).

To determine the effects of glucagon treatment on cardiovascular outcomes during MI, we treated mice with glucagon (3× daily, via subcutaneous injection, 30 ng/g body weight) prior to and following LAD coronary artery ligation ([Figure 1](#fig1){ref-type="fig"}A). No significant changes in random glycemia or body weight were observed with glucagon injections ([Supplementary Figure 1C,D](#appsec2){ref-type="sec"}), however, glucagon significantly reduced survival following MI and was associated with a significant increase in TUNEL-positive apoptotic cardiac myocytes (48 h post-MI), although no effect on adverse LV remodeling or infarct scar formation was observed ([Figure 1](#fig1){ref-type="fig"}B--D). These negative cardiovascular outcomes required p38 MAPK; glucagon increased p38 MAPK phosphorylation in both the aerobic and ischemic heart ([Figure 1](#fig1){ref-type="fig"}E), and co-treatment with SB203580 (p38 MAPK inhibitor) prevented the glucagon-mediated reduction in MI survival ([Figure 1](#fig1){ref-type="fig"}B), as well as the increase in TUNEL-positive cardiac myocytes ([Figure 1](#fig1){ref-type="fig"}D).

3.2. Glucagon activates PPARα in a p38 MAPK-dependent manner in cardiac myocytes, and increases cardiac myocyte apoptosis *in vitro* {#sec3.2}
------------------------------------------------------------------------------------------------------------------------------------

As glucagon increases hepatocyte PPARα activity in a p38 MAPK-dependent manner [@bib8], we examined whether similar regulation occurs in the heart. Treatment of HL-1 atrial cardiac myocytes (which do not express the endogenous Gcgr) with an adenovirus encoding the rat Gcgr (Ad*Gcgr*) followed by treatment with glucagon (20 nM) for 24 h increased the expression of PPARα target genes ([Figure 2](#fig2){ref-type="fig"}A). In contrast, no such changes were observed in HL-1 cells treated with a control adenovirus (Ad*β-Gal*, [Supplementary Figure 1E](#appsec2){ref-type="sec"}). Furthermore, glucagon (20 nM for 24 h) increased luciferase activity directed by a PPARα response element in Ad*Gcgr*-infected HL-1 cells ([Figure 2](#fig2){ref-type="fig"}B), but not in Ad*β-Gal*-infected HL-1 cells ([Supplementary Figure 1F](#appsec2){ref-type="sec"}). Furthermore, SB203580 abolished the glucagon-mediated increase in PPARα luciferase activity in Ad*Gcgr*-infected HL-1 cells, illustrating the dependency on p38 MAPK activity ([Figure 2](#fig2){ref-type="fig"}C). We also observed an increase in nuclear PPARα translocation in both glucagon-treated adult cardiac myocytes ([Figure 2](#fig2){ref-type="fig"}D) and Ad*Gcgr* infected HL-1 cells ([Figure 2](#fig2){ref-type="fig"}E), which was abolished by pre-treatment with SB203580 ([Figure 2](#fig2){ref-type="fig"}E).

We next determined whether pyruvate dehydrogenase (PDH, the rate-limiting enzyme of glucose oxidation) activity was altered in hearts and HL-1 cells treated with glucagon. Glucagon increased PDH phosphorylation (indicative of reduced PDH activity) in both the aerobic/ischemic heart ([Figure 2](#fig2){ref-type="fig"}F), and in HL-1 cells infected with Ad*Gcgr* ([Figure 2](#fig2){ref-type="fig"}G), but not in cells infected with Ad*β-Gal* ([Supplementary Figure 1G](#appsec2){ref-type="sec"}). Glucagon also increased hydrogen peroxide (H~2~O~2~)-induced caspase-3 cleavage, an effect negated via pretreatment with the PDH kinase inhibitor, dichloroacetate (DCA) ([Figure 2](#fig2){ref-type="fig"}H). Pre-treatment with DCA also reduced expression of the pro-apoptotic protein, Bax, but had no effect on expression of the anti-apoptotic protein, Bcl-2, in Ad*Gcgr*-infected HL-1 cells treated with H~2~O~2~ and glucagon ([Supplementary Figure 2](#appsec2){ref-type="sec"}).

3.3. Glucagon regulates acylcarnitine profiles in the heart {#sec3.3}
-----------------------------------------------------------

Although myocardial ischemia reduces fatty acid oxidation rates due to the reduction in oxygen supply, we observed a robust increase in long chain acylcarnitines in ischemic hearts 24-h post-glucagon and 30 min post-MI ([Figure 3](#fig3){ref-type="fig"}). The most likely interpretation of this profile is that glucagon triggered an increase in β-oxidation, but that flux through the TCA cycle, electron transport chain, and oxidative phosphorylation was limited by ischemia, resulting in accumulation of incompletely oxidized fats. Interestingly, Krebs cycle intermediates were not altered in glucagon-treated hearts ([Supplementary Figure 3](#appsec2){ref-type="sec"}), suggesting that the increase in fatty acid oxidation may have provided acetyl CoA for the Krebs cycle to offset the apparent decrease in PDH activity.

3.4. Cardiomyocyte-specific deletion of the Gcgr produces a cardioprotective phenotype in response to ischemic injury {#sec3.4}
---------------------------------------------------------------------------------------------------------------------

As increased glucagon action produces negative effects on the ischemic heart, we hypothesized that reducing glucagon action should protect against ischemic injury. Mice with global germline deletion of the *Gcgr* exhibit mild hypoglycemia, and increased levels of proglucagon-derived peptides, Fgf-21 and bile acids [@bib26; @bib33; @bib34; @bib35], complicating interpretation and mechanistic attribution of cardiac phenotypes arising from whole body loss of the *Gcgr*. Indeed, secondary increases in GLP-1 and Fgf-21 in *Gcgr*^−/−^ mice may exert independent cardioprotective actions [@bib36; @bib37]. Accordingly, we generated a tamoxifen-inducible cardiomyocyte-specific *Gcgr* knock out mouse (*Gcgr*^CM−/−^; [Supplementary Figure 4A](#appsec2){ref-type="sec"}). Treatment with tamoxifen (50 mg/kg IP) for 5 consecutive days decreased cardiac *Gcgr* mRNA expression by ∼85% without affecting *Gcgr* mRNA expression in the liver and kidney ([Supplementary Figure 4B--D](#appsec2){ref-type="sec"}). *Gcgr*^CM−/−^ mice appeared phenotypically normal, exhibiting normal weight gain and similar glucose tolerance relative to α myosin heavy chain-Cre (*αMHC*^Cre^) littermate controls ([Supplementary Figure 5](#appsec2){ref-type="sec"}). Following LAD coronary artery ligation, *Gcgr*^CM−/−^ mice exhibited a marked increase in survival, reduced cardiac hypertrophy, and substantially less adverse LV remodeling ([Figure 4](#fig4){ref-type="fig"}). A significant reduction in mRNA levels of (a) key PPARα target genes and (b) mRNA transcripts encoding regulators of lipid metabolism was detected in *Gcgr*^CM−/−^ aerobic hearts, with similar trends detected in ischemic hearts ([Figure 5](#fig5){ref-type="fig"}A). PPARα protein expression was also reduced in sham/aerobic but not in ischemic *Gcgr*^CM−/−^ hearts; ischemia alone reduced cardiac PPARα protein expression ([Figure 5](#fig5){ref-type="fig"}B). In contrast, levels of Akt and GSK3β phosphorylation were unaltered in ischemic hearts from *Gcgr*^CM−/−^ mice, but Akt phosphorylation was increased in aerobic/sham hearts from *Gcgr*^CM−/−^ mice ([Figure 5](#fig5){ref-type="fig"}B). Furthermore, PDH phosphorylation showed a trend towards reduction in both sham/aerobic and ischemic hearts from *Gcgr*^CM−/−^ mice ([Figure 5](#fig5){ref-type="fig"}B), consistent with a role for glucagon action in the control of cardiac PDH activity and glucose oxidation.

3.5. Acylcarnitine profiling suggests reduced myocardial fatty acid oxidation in Gcgr^CM−/−^ mice {#sec3.5}
-------------------------------------------------------------------------------------------------

We observed a significant reduction in several long chain acylcarnitine species in sham/aerobic hearts from *Gcgr*^CM−/−^ mice ([Figure 6](#fig6){ref-type="fig"}A), suggesting that eliminating glucagon action in heart reduces substrate burden on the fatty acid oxidation pathway. Consistent with the likelihood that this metabolic effect was specific to fatty acid oxidation and not an overall decrease in oxidative metabolism, we observed a decrease in medium chain acylcarnitines in sham/aerobic hearts from *Gcgr*^CM−/−^ mice, whereas myocardial C2 (acetylcarnitine) levels were similar between *Gcgr*^CM−/−^ and *αMHC*^Cre^ mice ([Figure 6](#fig6){ref-type="fig"}B). In addition, TAG content and the majority of Krebs cycle intermediates were similar in *Gcgr*^CM−/−^ and *αMHC*^Cre^ sham/aerobic hearts ([Figure 6](#fig6){ref-type="fig"}C--I). Similar results were observed in *Gcgr*^CM−/−^ and *αMHC*^Cre^ ischemic hearts 30 min post-MI, with the exception of an increase in myocardial TAG content in *Gcgr*^CM−/−^ hearts ([Figure 6](#fig6){ref-type="fig"}J--R). Ischemia itself reduces fatty acid oxidation and results in the mobilization of myocardial TAG stores (∼2.2 vs. 1.1 μmol/g wet weight in *αMHC*^Cre^ aerobic and ischemic hearts, respectively), but the additional reduction in fatty acid oxidation in *Gcgr*^CM−/−^ ischemic hearts likely explains their increase in myocardial TAG content relative to ischemic hearts from their *αMHC*^Cre^ littermates. Comparable results were observed in the hearts of *Gcgr*^CM−/−^ and *αMHC*^Cre^ mice fed a high fat diet for 6 months, with the majority of long chain acylcarnitines trending lower in *Gcgr*^CM−/−^ hearts ([Supplementary Figure 6](#appsec2){ref-type="sec"}).

3.6. Glucagon attenuates recovery of left ventricular developed pressure during ischemia/reperfusion injury {#sec3.6}
-----------------------------------------------------------------------------------------------------------

We next determined whether reduced or enhanced cardiac Gcgr signaling modulates outcomes in response to *ex vivo* ischemia/reperfusion (I/R) injury. Isolated hearts from *Gcgr*^−/−^ mice exhibited enhanced recovery of LV developed pressure (LVDP) following I/R injury, whereas glucagon treatment impaired recovery of LVDP in isolated hearts from WT mice ([Figure 7](#fig7){ref-type="fig"}A--F).

3.7. Glucagon fails to increase mortality or impair LV remodeling in ischemic Gcgr^CM−/−^ mice {#sec3.7}
----------------------------------------------------------------------------------------------

To determine whether the glucagon-induced increase in mortality and adverse LV remodeling following MI ([Figure 1](#fig1){ref-type="fig"}) was due to direct activation of the cardiac glucagon receptor, we treated *Gcgr*^CM−/−^ mice and their *αMHC*^Cre^ littermates with glucagon (30 ng/g body weight; 3× daily, via subcutaneous injection) prior to and following LAD coronary artery ligation. Although glucagon increased mortality and infarct size in *αMHC*^Cre^ control mice, it had no effect on these parameters in *Gcgr*^CM−/−^ mice ([Figure 7](#fig7){ref-type="fig"}G,H). Hence the deleterious effects of glucagon on the cardiac response to ischemic injury are not indirect and require a functional cardiomyocyte Gcgr.

4. Discussion {#sec4}
=============

Our findings demonstrate that exogenous glucagon administration has negative actions on the ischemic heart, whereas reduction in cardiac glucagon action in *Gcgr*^CM−/−^ mice results in marked cardioprotection. In both situations, changes in fatty acid oxidation correlate with cardiac outcomes, as multiple long-chain acylcarnitines are increased by glucagon in the ischemic heart, whereas *Gcgr*^CM−/−^ mice have reduced levels of these metabolites under ischemic conditions. Taken together these findings strongly and independently support the importance of both pharmacological and physiological Gcgr signaling in the cardiac response to ischemic injury.

Previous studies have provided conflicting data on the role of glucagon on the myocardium. Treatment with glucagon worsened the recovery of cardiac power in the isolated working rat heart during global no-flow ischemia/reperfusion [@bib16] and cardiomyopathy developed in a patient with a glucagonoma that was completely reversed upon tumor resection [@bib38]. In contrast, glucagon improved LV minute work and contractility in dogs with acute MI [@bib39]. Furthermore, glucagon administration to 6 patients with AMI produced positive inotropic effects and temporarily improved cardiogenic shock [@bib40], whereas glucagon increased cardiac performance and reduced LV failure without altering myocardial oxygen consumption in dogs subjected to MI [@bib41]. Although heart rate and systolic blood pressure trended lower in non-ischemic *Gcgr*^CM−/−^ mice (data not shown), these differences were not statistically significant perhaps due to the small number of animals analyzed. Our results support the contention that pharmacological glucagon agonism is deleterious to the ischemic heart, as glucagon significantly enhanced mortality following MI, whereas *Gcgr*^CM−/−^ mice exhibited a cardioprotective phenotype following LAD coronary artery ligation-induced myocardial injury. Thus, reduction of glucagon receptor signaling in the heart should be explored as a novel approach for the attenuation of ischemic myocardial injury. However, whether cardiac GCGR signaling can be safely, selectively and effectively targeted pharmacologically in humans without incurring additional systemic liabilities is currently unknown.

Although the mechanism(s) via which glucagon receptor signaling modulates cardiovascular outcomes following MI remain incompletely identified, changes in myocardial fatty acid oxidation appear to be implicated. Acylcarnitine profiling indicated that glucagon caused accumulation of incompletely oxidized lipids in the heart, as has also been seen in experimental models of heart failure [@bib42]. In skeletal muscle, accumulation of acylcarnitines has been described in obesity and type 2 diabetes. Relief of acylcarnitine accumulation by reducing entry of fatty acids into the mitochondria relieves substrate overload and enhances insulin action [@bib24] and conversely, increasing acyl CoA/acylcarnitine accumulation by transgenic knockout of carnitine acyl transferase (CrAT) impairs insulin sensitivity [@bib43]. Here, we observed increased acylcarnitines in response to glucagon administration in the ischemic heart, consistent with activation of the early, but not later phases of fatty acid oxidation, whereas heart-specific deletion of Gcgr appeared to reduce substrate pressure on the fatty acid oxidation pathway. Consistent with the metabolic profile, glucagon treatment of cardiac myocytes increased PPARα activity, a known activator of the β-oxidative machinery, whereas PPARα downstream target gene mRNA expression was reduced in hearts from *Gcgr*^CM−/−^ mice.

PPARα is a key regulator of fatty acid oxidation in the heart [@bib44; @bib45] and cardiac-specific PPARα overexpression (a) worsens the recovery of cardiac function during *ex vivo* I/R injury in the isolated working heart [@bib46] and (b) induces a diabetic-like cardiomyopathy [@bib45]. Furthermore, genetic elimination of PPARα in dominant-negative NADPH oxidase transgenic mice reversed their increased infarct size and cardiac myocyte apoptosis in response to *in vivo* I/R injury [@bib47] and elimination of PPARα in cardiac-specific aryl hydrocarbon nuclear translocator deficient mice reversed their associated cardiomyopathy and lipotoxicity [@bib48]. Likewise, PPARα deficient mice are protected against both *ex vivo* I/R injury and streptozotocin-induced diabetic cardiomyopathy [@bib46; @bib49]. In contrast, treatment with the PPARα agonist, GW7647, reduced infarct size in CD1 mice following temporary occlusion of the LAD coronary artery [@bib50] whereas the PPARα agonist, fenofibrate, improved recovery following *ex vivo* I/R injury in hearts from mice with diet-induced obesity [@bib51]. While direct PPARα agonism increases fatty acid oxidation, chronic peripheral PPARα agonism actually increases hepatic fatty acid oxidation rates, which decreases circulating lipids without changes in cardiac PPARα activity [@bib51]. Acknowledging the ongoing controversy regarding PPARα agonism, fatty acid oxidation and ventricular function, our findings with glucagon are consistent with a negative role for Gcgr-dependent PPARα activity in the ischemic heart.

Consistent with previous studies of glucagon action in the liver [@bib8] we demonstrated that glucagon activates PPARα in the heart in a p38 MAPK dependent manner. However, p38 MAPK has also been demonstrated to increase cardiac injury through mechanisms independent of changes in fatty acid oxidation, such as an increase in intracellular acidosis which decreases the efficiency of contractile function [@bib52] or via interaction with TAK1-binding protein 1 to enhance cardiac myocyte apoptosis [@bib53]. Thus, other mechanisms may also contribute to our observed phenotypes via activation of p38 MAPK activity.

Our current studies have several important limitations. First, the majority of our experiments were performed in relatively young, healthy, non-diabetic, non-obese mice. Perturbations of the normal metabolic environment may greatly influence myocardial energy uptake, patterns of fuel utilization, and potentially, cardiovascular outcomes. Moreover, the role(s) of and pathways activated by enhanced or disrupted cardiac Gcgr signaling in the ischemic myocardium of older mice with established cardiovascular disease may be different. Furthermore, it cannot be assumed that gain and loss of Gcgr signaling in the normal, diabetic, or obese human heart will produce similar deleterious or beneficial outcomes. Notably, we have not ascertained whether the acute negative actions of glucagon on the mouse heart reflect achievement of a critical Cmax or total exposure to glucagon. Moreover, whether sustained exposure to glucagon would result in partial desensitization of the cardiac Gcgr signaling pathway has not been examined. Of potential relevance to future studies of the Gcgr and related cyclic AMP-linked cardiac receptors, a recent report described cardioprotective actions of secreted cyclic AMP metabolized to adenosine, which differs substantially from the classical cardiotoxic effects of intracellular cyclic AMP [@bib54]. Hence understanding the effects of glucagon and GLP-1 on intracellular vs. secreted cyclic AMP in the heart may be important. Finally, our experiments focused on the consequences of ischemic cardiac injury, and the importance of Gcgr signaling in experimental models of heart failure under normoglycemic and diabetic conditions requires further elucidation.

There is currently great interest in the therapeutic potential of glucagon/GLP-1 co-agonists and glucagon-containing tri-agonists for the treatment of obesity and/or diabetes [@bib7; @bib10; @bib55]. Our findings demonstrate that pure unopposed acute glucagon agonism has negative effects on the myocardium during ischemic injury, whereas cardiomyocyte-specific elimination of glucagon receptor activity results in robust cardioprotection against MI-induced mortality and adverse LV remodeling. Nevertheless, we did not assess a full range of glucagon doses in our gain of function studies, hence it may be possible to administer glucagon at doses that prevent hypoglycemia (type 1 diabetes), or achieve some degree of weight loss (diabetes and/or obesity), without cardiotoxicity. Whether the combination of glucagon with GLP-1 agonism in the same molecule or as a mixture of two different agonists, will similarly mitigate the potential adverse consequences of unopposed Gcgr activation on the ischemic diabetic heart is an important question [@bib13]. Indeed, observations using the isolated rat perfused heart model suggest that glucagon alone compromised the energetic state of ischemic hearts, whereas a glucagon-GLP-1 dual agonist exerted preferential actions on cardiac energetics without increasing levels of cyclic AMP accumulation, thereby mitigating the adverse effects of glucagon [@bib56]. Furthermore, it cannot be assumed that administration of GCGR antagonists to diabetic subjects, at doses resulting in partial attenuation of GCGR signaling in multiple tissues, will produce a cardiovascular phenotype that mirrors or overlaps our findings in non-diabetic mice with marked selective genetic reduction of Gcgr signaling in cardiomyocytes.

Similar questions surround the dose--response relationships for the cardiovascular actions of glucagon in subjects with type 1 diabetes and pre-existing coronary artery disease. Indeed, the investigational use of combined glucagon-insulin delivery systems for the optimized treatment of type 1 diabetes [@bib57] emphasizes the need to explore the safety of a range of glucagon concentrations in humans at risk for cardiovascular events. Our data highlights the importance of understanding the cardiovascular actions of novel peptide therapies being evaluated for the treatment of patients with metabolic disorders associated with a substantial concomitant risk of developing ischemic heart disease.
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The following are the supplementary data related to this article:

Supplementary Figure 1. G protein-coupled receptor expression in the heart. Glycemia and body weight in mice following glucagon treatment, and the effect of glucagon on PPARα target gene expression and PPARα-directed luciferase activity in Ad*β-gal* transduced HL-1 cells. (A) Mouse G-protein-coupled receptor transcripts were identified in RNA isolated from individual right atrium (RA), left atrium (LA), right ventricle (RV), and left ventricle (LV) from C57BL/6 mice following reverse transcription-PCR with gene-specific primers that amplify products encompassing the majority of the open reading frame. Southern blotting with an internal ^32^P-labeled oligonucleotide was used to detect each product. Expected size of full-length PCR product is indicated by the arrow on the left of each panel. Lung and islet were used as positive controls for glucagon-like peptide-1 receptor (*Glp1r*) expression. White adipose tissue (WAT) and islet were used as positive controls for glucose-dependent insulinotropic polypeptide receptor (*Gipr*) expression. Liver (Liv) was used as a positive control for glucagon receptor (*Gcgr*) expression. Jejunum (Jej) was used as a positive control for glucagon-like peptide-2 receptor (*Glp2r*) expression. Ec1 and Ec2 are from mouse primary endothelial cell preparations. The following primers were used for RT-PCR: *Glp1r*: Forward: GTACCACGGTGTCCCTCTCA: Reverse: CCTGTGTCCTTCACCTTCCCTA Internal: GGATGGGCTCCTCTCCTAAT: *Gipr*: Forward: CTGCTTCTGCTGCTGTGGT Reverse: CACATGCAGCATCCCAGA Internal: GTCTGCAGGCTTTGTCTTCC: *Gcgr*: Forward: CTGCTGCTGCTGCTGTTGG Reverse: ACCTTGGGAGACTACTGGC Internal: GGATTCTGGTGGATCCTGCG: *Glp2r*: Forward: CTGCTGGTTTCCATCAAGCAA Reverse: TAGATCTCACTCTCTTCCAGA Internal: GCACACGCAATTACATCCAC. (B) G-protein-couple receptor gene expression was examined in RNA isolated from combined left and right atria or combined left and right ventricle samples from a single C57BL/6 mouse using real-time PCR. mRNA levels of the indicated genes are expressed relative to cyclophilin mRNA levels. *Glp2r*, glucagon-like peptide-2 receptor; *Glp1r*, glucagon-like peptide-1 receptor, *Gcgr*, glucagon receptor; *Gipr*, glucose-dependent insulinotropic polypeptide receptor. List of real-time primers (Applied Biosystems Inc.) are as follows: *Glp2r*-Mm00558835_m1: *Glp1r*-Mm0135008_m1: *Gcgr*-Mm00433546_m1: *Gipr*-Mm01316344_m1; PPIA-Mm02342430_m1. (C) Random morning non-fasted glucose and (D) body weight in mice repeatedly injected with glucagon as per the schedule shown in [Figure 1](#fig1){ref-type="fig"}A. (E) HL-1 cells transduced with Ad*β-gal* were treated with saline or 20 nM glucagon for 3 h following which RNA was isolated for mRNA expression analysis. Data are mean ± S.E.M (*n* = 5). (F) HL-1 cells were transduced with Ad*β-gal* for 24 h followed by transfection with a PPAR-α reporter gene-luciferase construct for another 24 h and luciferase expression was assessed. Data are mean ± S.E.M (*n* = 5). (G) HL-1 cells transduced with Ad*β-gal* for 24 h followed by a 3 h treatment with 20 nM glucagon. Cell lysates were analyzed by Western blotting for expression of P-PDH and total PDH. Data are mean ± S.E.M (*n* = 5).

Supplementary Figure 2. Glucagon increases Bax protein expression in H~2~O~2~ treated Ad*Gcgr* transduced HL-1 cells. (A, B) Bax and Bcl-2 protein expression in HL-1 cells infected with Ad*Gcgr* for 24 h followed by 24 h treatment with 100 μM H~2~O~2~ and 20 nM glucagon during the final 3 h of H~2~O~2~ treatment. Another group was also treated concomitantly with 1.5 mM DCA (PDH activator via inhibition of the PPARα target gene, PDK4) during H~2~O~2~ treatment.

Supplementary Figure 3. Krebs cycle intermediates in aerobic and ischemic hearts. (A--E) Levels of Krebs cycle intermediates in aerobic or ischemic hearts harvested 30 min following LAD coronary artery ligation or sham surgery in mice injected with glucagon (30 ng/g) or saline (every 8 h for 24 h) (*n* = 5 per group).

Supplementary Figure 4. Generation and characterization of *Gcgr*^CM−/−^ mice. (A) *Gcgr*^Flox^ mice were mated with FLPe mice to remove the neomycin resistance cassette [@bib9]. The resulting *Gcgr*^Flox^ mice were then mated with *αMHC*^Cre^ mice to generate *Gcgr*^CM−/−^ mice. *Gcgr* mRNA expression in *Gcgr*^CM−/−^ and control mice in liver (B), kidney (C) and heart (D). \**p* \< 0.05 *Gcgr*^CM−/−^ vs. littermate control mice. Data are mean ± S.E.M (*n* = 5--6 per genotype).

Supplementary Figure 5. Body weight and glucose tolerance in *Gcgr*^CM−/−^ and control mice. (A) Body weight was monitored from 7 to 14 weeks of age before and after tamoxifen injections in *Gcgr*^CM−/−^ and littermate control mice. (B) Blood glucose levels during an oral glucose tolerance test in 10- to 14-week-old mice (*n* = 11--22 mice per group). Plasma insulin levels at 0 and 15 min following oral glucose challenge (*n* = 4--9 mice per group). (C) Blood glucose levels during an intraperitoneal glucose tolerance test in 10- to 14-week-old mice (*n* = 11--22 mice per group). Plasma insulin levels at 0 and 15 min following intraperitoneal glucose challenge (*n* = 4--9 mice per group). Data are mean ± S.E.M.Supplementary Figure 6. Targeted metabolomics reveals reduced fatty acid oxidation in hearts from high fat fed *Gcgr*^CM−/−^ mice. Acylcarnitine levels in aerobic hearts harvested from 5 h fasted *αMHC*^Cre^ and *Gcgr*^CM−/−^ mice that had been maintained on a high fat diet for 6 months (*n* = 5 per genotype). Values are expressed as percent of *αMHC*^Cre^ mice values.
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![Glucagon impairs survival after MI in a p38 MAPK-dependent manner. (A) Schematic of overall study design. Mice were injected with vehicle/glucagon/SB203580 for 7 days starting 1 day prior to LAD coronary artery ligation and sacrificed 15 days later. (B) Survival following LAD coronary artery ligation in C57BL/6 mice treated with saline or glucagon (30 ng/g) with or without co-administration of the p38 MAPK inhibitor (SB203580 1 μmol/kg) for 1 week. \**p* \< 0.05 saline vs. glucagon. Data are mean ± S.E.M (LAD *n* = 13--15 per treatment). (C) Infarct size assessed in mice described in (B) at day 15. Data are mean ± S.E.M (LAD *n* = 5--6 per treatment). (D) C57BL/6 mice treated with saline or glucagon (30 ng/g) with or without co-administration of the p38 MAPK inhibitor (SB203580 1 μmol/kg; SB) were subjected to LAD coronary artery ligation for 48 h to assess TUNEL positive cardiac myocytes. \**p* \< 0.05 saline vs. glucagon. Data are mean ± S.E.M (LAD *n* = 7--8 mice per treatment). (E) p38 MAPK phosphorylation in C57BL/6 mice treated with saline or glucagon (30 ng/g) with or without SB203580 (1 μmol/kg) 48 h post-LAD coronary artery ligation or sham surgery. \**p* \< 0.05 saline vs. glucagon group. Data are mean ± S.E.M (*n* = 3--5).](gr1){#fig1}

![Glucagon increases PPARα-dependent gene expression, PPARα nuclear translocation, cleaved caspase 3 levels, and PDH phosphorylation. (A) HL-1 cells infected with adenovirus expressing the rat *Gcgr* cDNA were treated with saline or 20 nM glucagon for 3 h for assessment of *Cpt1b*, *Dgat1*, *Dgat2*, and *Acox* mRNA expression. (B,C) HL-1 cells were infected with Ad*β-gal* or Ad*Gcgr* for 24 h followed by transfection with a PPARα gene promoter-luciferase construct. Cells were treated with saline or 20 nM glucagon for 3 h, with or without the PKA inhibitor (H89) or p38 MAPK inhibitor (SB203580) and luciferase expression was quantified as Relative Light Units (RLU). (D) Primary cultures of murine atrial cardiac myocytes were treated with saline or 20 nM glucagon for 3 h and cells were harvested for Western blot analysis of cytoplasmic and nuclear protein expression. (E) HL-1 cell lines infected with Ad*Gcgr* were treated with saline or 20 nM glucagon with and without SB203580 and cells were harvested for nuclear (N) and cytoplasmic (C) protein analysis. (F) C57BL/6 mice were treated with exogenous glucagon (30 ng/g) every 8 h for 24 h to assess PDH phosphorylation in hearts in mice that underwent 30 min occlusion of the LAD coronary artery or sham surgery (*n* = 6 per treatment). (G) PDH phosphorylation in HL-1 cells infected with Ad*Gcgr* for 24 h followed by a 3 h treated with glucagon. (H) Ad*Gcgr* infected HL-1 cell lines were treated for 24 h with 100 μM H~2~O~2~ and/or 20 nM glucagon during the final 3 h of H~2~O~2~ treatment to detect cleaved caspase 3 levels. Separate groups of cells were treated with or without 1.5 mM DCA (PDH activator via inhibiting the PPARα target gene, PDK4) for 24 h concomitantly with H~2~O~2~. \**p* \< 0.05, saline vs. glucagon. ^\#^*p* \< 0.05, glucagon + SB203580 vs. glucagon alone. All cell culture experiments were repeated at least twice, *n*-4-6 per condition.](gr2){#fig2}

![Glucagon increases long chain acylcarnitine levels in the ischemic heart. Glucagon (30 ng/g body weight) or saline injections were administered subcutaneously every 8 h over a 24 h period (4 total injections at 0, 8, 16, and 24 h) and hearts were harvested after a 5 h fast and subjected to metabolomics assessment to determine acylcarnitine content. Ischemic hearts were collected 30 min following LAD coronary artery ligation surgery (surgery took place 4 h into the 5 h fast). Data is expressed as percent of levels in aerobic mouse hearts for each respective group.\**p* \< 0.05 saline vs. glucagon-treated LAD coronary artery ligation group. Data are mean ± S.E.M (*n* = 5 per group).](gr3){#fig3}

![Loss of cardiac *Gcgr* signaling enhances survival following MI and attenuates adverse LV remodeling. (A) LAD coronary artery ligation was performed in 11--14-week-old *Gcgr*^CM−/−^ and littermate control mice and survival was monitored for 15 days following surgery. \**p* \< 0.05 *Gcgr*^CM−/−^ vs. each control group. Data are mean ± S.E.M (SHAM; *n* = 10 per genotype and LAD; *n* = 11--23 per genotype). (B) Heart weight:body weight (HW:BW) ratio 15 days following LAD coronary artery ligation. \**p* \< 0.05 *Gcgr*^CM−/−^ vs. *Gcgr*^Flox^ and wild-type (WT) mice. Data are mean ± S.E.M (*n* = 8--11 per genotype). (C) Masson\'s trichome staining of infarcted heart and quantification of % left ventricular (LV) infarct scar area 15 days following LAD coronary artery ligation. \**p* \< 0.05 *Gcgr*^CM−/−^ vs. littermate control mice. Data are mean ± S.E.M (*n* = 9--11 per genotype).](gr4){#fig4}

![Selective loss of Gcgr signaling in cardiomyocytes leads to reduced expression of genes and proteins regulating fatty acid metabolism. (A) Quantification of mRNA transcript levels from sham/aerobic and ischemic hearts (30 min post-LAD coronary artery ligation) from 12-week-old *αMHC*^Cre^ and *Gcgr*^CM−/−^ mice fasted for 5 h (*n* = 4). \**p* \< 0.05 *Gcgr*^CM−/−^ vs. *αMHC*^Cre^. Data are mean ± S.E.M. (B) Protein expression/phosphorylation in fasted (5 h) hearts from 12-week-old *αMHC*^Cre^ and *Gcgr*^CM−/−^ mice subjected to sham surgery or LAD coronary artery occlusion for 30 min \**p* \< 0.05 for *αMHC*^Cre^ vs. *Gcgr*^CM−/−^ mice. Data are mean ± S.E.M (*n* = 4 mice in each group).](gr5){#fig5}

![Targeted metabolomics reveals reduced fatty acid oxidation in *Gcgr*^CM−/−^ hearts. (A) Acylcarnitine levels in aerobic hearts harvested from fasted (5 h) *αMHC*^Cre^ and Gcgr^CM−/−^ mice (*n* = 5 per genotype). Values are expressed as percent of levels in hearts from *αMHC*^Cre^ mice. (B) Aerobic myocardial total long chain (LC), medium chain (MC) and acetyl (C2) acylcarnitines.\**p* \< 0.05 *αMHC*^Cre^ vs. *Gcgr*^CM−/−^. Levels of triacylglycerol (TAG) (C), lactate (D) and Krebs cycle intermediates (E--I) in 5 h fasted sham/aerobic hearts. \**p* \< 0.05 *αMHC*^Cre^ vs. *Gcgr*^CM−/−^. (J) Acylcarnitine levels in hearts harvested 30 min following cardiac ischemia from 5 h fasted *αMHC*^Cre^ and *Gcgr*^CM−/−^ mice (*n* = 5 per genotype). Values are expressed as percent of *αMHC*^Cre^ mice values. (K) Levels of total LC, MC and acetyl (C2) acylcarnitines in ischemic hearts.\**p* \< 0.05 *αMHC*^Cre^ vs. *Gcgr*^CM−/−^. TAG (L) and lactate (M) content in ischemic hearts. \**p* \< 0.05 *αMHC*^Cre^ vs. *Gcgr*^CM−/−^. (N--R) Levels of Krebs cycle intermediates in hearts harvested 30 min following cardiac ischemia from 5 h fasted *αMHC*^Cre^ and *Gcgr*^CM−/−^ mice. \**p* \< 0.05 *αMHC*^Cre^ vs. *Gcgr*^CM−/−^.](gr6){#fig6}

![Loss of *Gcgr* signaling protects whereas glucagon impairs recovery of LV developed pressure (LVDP) after I/R injury in the isolated heart *ex vivo*. (A--F) Schematic depiction of peptide infusions, ischemia and reperfusion times, and representative LVDP recordings and data from isolated perfused hearts. LVDP measurements in isolated perfused *Gcgr*^−/−^ (B,E) and WT (D,F) hearts subjected to I/R injury with and without glucagon (1 μg/mL for 20 min) (D,F). For E&F, graph depicts the percentage recovery rate of LVDP following ischemia. Data shown are means ± S.E.M. (*n* = 3--6 per genotype). *\*p* \< 0.05 compared with the control group. (G,H) Glucagon impairs survival after myocardial infarction in a cardiac *Gcgr*-dependent manner. (G) Left anterior descending coronary artery ligation (LAD) surgeries were performed in 11--14-week-old *αMHC*^Cre^ and *Gcgr*^CM−/−^ mice treated with 30 ng/g body weight glucagon given by subcutaneous injection (every 8 h for 7 days). Survival was monitored for 15 days following surgery. (H) Infarct size was assessed 15 days following LAD coronary artery ligation. \**p* \< 0.05 *αMHC*^Cre^ WT vs. *Gcgr*^CM−/−^ mice. Data are mean ± S.E.M (*n* = 12--13 per genotype).](gr7){#fig7}
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